<DOC>
	<DOCNO>NCT02206308</DOCNO>
	<brief_summary>The purpose study determine whether SCT400 safe effective treatment B-cell Non Hodgkin 's lymphoma</brief_summary>
	<brief_title>Safety , Pharmacokinetics Pharmacodynamics Recombinant Chimeric Anti-CD20 Monoclonal Antibody Patients With B-cell Non-Hodgkin 's Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>age 18 75 year histologically confirm NHL express CD20 antigen relapse nonHodgkin 's lymphoma ( NHL ) least one prior course standard therapy Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 accord WHO scale , expect survival least ≥ 3 month sign informed consent form approve institutional review board respective medical center single measurable lesion ≥7 cm diameter serious hematologic dysfunction ( white blood cell count &lt; 3.0×103/μL ; absolute neutrophil count &lt; 1.5×103/ μL ; platelet count &lt; 75×103/μL ; hemoglobin level &lt; 8.0 g/dL ; serum immunoglobulin G ( IgG ) level &lt; 600 mg/dL ) ; , hepatic dysfunction ( total bilirubin level &gt; 1.5×upper limit normal（ULN） ; aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) level &gt; 2.5 × ULN ( ≥5 × ULN patient liver metastasis ) ) ; renal dysfunction ( serum creatinine level &gt; 1.5×ULN ) least 4 week beyond prior anticancer therapy include corticosteroid , participate clinical trial recover significant toxicity prior therapy receive rituximab antiCD20 ( + ) monoclonal antibody treatment within 1 year enrollment receive hematopoietic cytokine , e.g CSF、EPO within 1 week prior study entry malignancy ; central nervous system ( CNS ) lymphoma , AIDS relate lymphoma ; active opportunistic infection , serious nonmalignant disease hepatitis B virus surface antigen /or antibodies hepatitis C virus human immunodeficiency virus pleural effusion ascites secondary lymphoma ; high risk tumor lysis syndrome ; recent major surgery ( within 28 day ) history allergic reaction protein product allergy include murine protein pregnant lactate accepted birth control method include male patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Chimeric anti-CD20 monoclonal antibody ( SCT400 )</keyword>
	<keyword>escalate dos</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics pharmacodynamics</keyword>
</DOC>